{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Modern Midlife Collective","title":"Episode 41: The Estrogen Lie, Revisited","html":"","width":"100%","height":180,"duration":1794,"description":"Back in Episode 20, Dr. Jill and Dr. Ade covered the FDA's decision to walk back twenty years of black box warnings on hormone therapy. Since then, hormone therapy has become a genuine moment on social media, and not always an accurate one. In this quick-turnaround update, they separate what the newest research actually shows from what the internet is claiming, including a new Stanford study linking estrogen-only therapy to lower Alzheimer's markers, why that finding does not extend to combined therapy, and what the twenty-year-old dementia data really pins the risk on.\n\nSegment Guide\nCold open: What changed since Episode 20, and why this update exists\nThe quick WHI recap, done right: relative risk versus absolute risk, and the age-stratified \"timing hypothesis\"\nWhat the FDA actually changed, and when: the November 2025 label update, and what stayed in place\nWhat's actually prescribed now versus what WHI tested: bioidentical estradiol and micronized progesterone versus the oral synthetic combination used in the original trial, including how the two progestogens differ at the receptor level\nThe hype swing of 2026: what hormone therapy is well-supported for, and what it is not\nThe new Stanford Alzheimer's study: what its three parts can and cannot tell us, and why the dementia-risk signal from 2003 traces to one specific drug, not to progesterone as a category\nWhat we'd actually tell a patient: an honest, evidence-based bottom line\nKey Takeaways\nThe WHI's real numbers are absolute, not relative: about 8 additional breast cancer cases per 10,000 women per year in the combined-therapy arm, not the large-sounding relative-risk percentage that made headlines in 2002.\nEstrogen-alone therapy showed fewer breast cancer cases in the WHI, a reduction that reached statistical significance in longer-term follow-up along with a reduction in breast cancer mortality.\nToday's typical prescription, transdermal estradiol with micronized progesterone, is a different drug, different...","thumbnail_url":"https://img.transistorcdn.com/vSb4RMla_S75bpWB9Zxjk3g6nojoX9zmEdCD7Xe_JSw/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kMTZj/YjIwZGE1ZTU5Mjk2/NmU2NTU1NmM3N2Ni/ZTc0MC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}